New Bull's-Eyes for Drugs

A familiar class of cell-surface receptors turns out to offer an array of fresh targets that could yield new treatments for disorders ranging from HIV infection to obesity
or subscribe to access the full article.

An amazing fraction--roughly half--of all the medicines prescribed today have a striking commonality. At the molecular level, they act on the same type of target: a serpentine protein that weaves seven times through the membrane that envelops the cell. External parts of each serpent serve as an antenna for molecular signals approaching the cell, and internal parts trigger the cell's responses to such cues, beginning with the activation of a signal processor called a G-protein. The serpents themselves are thus known as G-protein coupled receptors, or GPCRs.

As a group, GPCRs show far more versatility than any other class of cell-surface receptor. For instance, the natural molecules to which GPCRs respond range in size from neurotransmitters that are only a few times as massive as a single carbon atom all the way up to proteins 75 times larger than that. Moreover, GPCRs participate in just about every bodily function that sustains life, from heartbeat and digestion to breathing and brain activity. The drugs that target these receptors are equally diverse. The list includes blood pressure reducers (such as propranolol), stomach acid suppressors (such as ranitidine), bronchodilators (such as albuterol) and antidepressants (such as paroxetine). The disorders these medicines treat include hypertension, congestive heart failure, ulcer, asthma, anxiety, allergy, cancer, migraine and Parkinson's disease.

or subscribe to access the full article.
Buy Digital Issue $7.99
Print + Digital
All Access
$99.99 Subscribe
Rights & Permissions
Share this Article:


You must sign in or register as a member to submit a comment.

Starting Thanksgiving

Enter code: HOLIDAY 2015
at checkout

Get 20% off now! >


Email this Article